TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER).

How it works

Travasol 2.75% in Dextrose 15% is a parenteral nutrition solution. Travassol provides amino acids for protein synthesis, while dextrose provides caloric energy. The mechanism involves intravenous administration to bypass gastrointestinal absorption, directly delivering substrates for metabolism and tissue repair.

What the body does with it

Metabolism	Amino acids undergo hepatic metabolism via transamination and deamination; dextrose is metabolized via glycolysis and oxidative phosphorylation. Insulin promotes cellular uptake.
Excretion	Travasol 2.75% in dextrose 15% is a parenteral nutrition solution. The amino acids are metabolized and their nitrogen is primarily excreted as urea in urine (renal >90%), with minimal biliary or fecal elimination. Dextrose is metabolized to CO2 and water, exhaled via lungs and excreted renally.
Half-life	Not applicable as a direct drug; components have variable half-lives: amino acids are rapidly cleared (minutes to hours), dextrose is regulated by insulin (glucose half-life ~1-2 hours in euglycemia).
Protein binding	Not significant for amino acids or dextrose; amino acids are unbound (<10%), dextrose does not bind to proteins.
Volume of Distribution	Amino acids distribute similar to extracellular fluid (~0.2-0.3 L/kg); dextrose distributes in total body water (~0.6 L/kg).
Bioavailability	Intravenous: 100% (directly enters systemic circulation).
Onset of Action	Intravenous: Nutritional effects begin within minutes as amino acids and dextrose enter systemic circulation; metabolic effects (protein synthesis, glucose utilization) occur within hours.
Duration of Action	Intravenous: Nutrient provision lasts as long as infusion continues; metabolic effects persist for hours after cessation, depending on individual metabolic state.

Classification & Brands

Dosing & administration

Intravenous infusion: 1000-2000 mL/day (providing 27.5 g amino acids and 150 g dextrose) at a rate not exceeding 4 mL/kg/hour.

Dosage form	INJECTABLE
Renal impairment	GFR <50 mL/min: Use with caution; monitor serum electrolytes and osmolarity. Reduce dose or use renal-specific amino acid formulation if severe impairment (GFR <25 mL/min).
Liver impairment	Child-Pugh B or C: Contraindicated; avoid in hepatic encephalopathy. In mild impairment (Child-Pugh A), use with caution and monitor ammonia.
Pediatric use	Weight-based: 1.5-3 g/kg/day of amino acids (equivalent to 54-109 mL/kg/day of this solution) with dextrose 3-6 mg/kg/min. Titrate based on metabolic tolerance.
Geriatric use	Elderly: Initiate at lower doses (e.g., 50-75% of standard) due to decreased renal function; monitor fluid and electrolyte balance closely; use with caution in heart failure.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER).

Breastfeeding	Travasol 2.75% in Dextrose 15% is a standard component of parenteral nutrition; components are normally present in human milk. No specific M/P ratio available. Use during lactation is considered safe when medically indicated.
Teratogenic Risk	Parenteral amino acid and dextrose solutions are essential nutrients; no teratogenic risk documented in first trimester. Use in second and third trimesters is common for maternal nutritional support without known fetal harm. However, hyperglycemia or electrolyte imbalances from improper administration may indirectly affect fetal development.

Warnings & precautions

■ FDA Black Box Warning

Not for use in patients with severe metabolic acidosis, hypersensitivity to any component, or inborn errors of amino acid metabolism. Risk of pulmonary edema due to fluid overload, especially in renal/cardiac impairment. Hyperglycemia or hypoglycemia may occur with dextrose infusion.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Severe metabolic acidosis or hyperglycemia","Hypersensitivity to any component","Inborn errors of amino acid metabolism (e.g., phenylketonuria)","Severe hepatic failure or encephalopathy","Uncontrolled diabetes"]

Clinical Precautions

Precautions

["Monitor fluid and electrolyte balance, blood glucose, and liver function regularly","Use with caution in renal/hepatic impairment, heart failure, diabetes mellitus","Risk of refeeding syndrome in severely malnourished patients","Do not administer if solution is discolored or contains particulate matter"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Amino acids undergo hepatic metabolism via transamination and deamination; dextrose is metabolized via glycolysis and oxidative phosphorylation. Insulin promotes cellular uptake.
Excretion	Travasol 2.75% in dextrose 15% is a parenteral nutrition solution. The amino acids are metabolized and their nitrogen is primarily excreted as urea in urine (renal >90%), with minimal biliary or fecal elimination. Dextrose is metabolized to CO2 and water, exhaled via lungs and excreted renally.
Half-life	Not applicable as a direct drug; components have variable half-lives: amino acids are rapidly cleared (minutes to hours), dextrose is regulated by insulin (glucose half-life ~1-2 hours in euglycemia).
Protein binding	Not significant for amino acids or dextrose; amino acids are unbound (<10%), dextrose does not bind to proteins.
Volume of Distribution	Amino acids distribute similar to extracellular fluid (~0.2-0.3 L/kg); dextrose distributes in total body water (~0.6 L/kg).
Bioavailability	Intravenous: 100% (directly enters systemic circulation).
Onset of Action	Intravenous: Nutritional effects begin within minutes as amino acids and dextrose enter systemic circulation; metabolic effects (protein synthesis, glucose utilization) occur within hours.
Duration of Action	Intravenous: Nutrient provision lasts as long as infusion continues; metabolic effects persist for hours after cessation, depending on individual metabolic state.

Classification & Brands

Dosing & administration

Intravenous infusion: 1000-2000 mL/day (providing 27.5 g amino acids and 150 g dextrose) at a rate not exceeding 4 mL/kg/hour.

Dosage form	INJECTABLE
Renal impairment	GFR <50 mL/min: Use with caution; monitor serum electrolytes and osmolarity. Reduce dose or use renal-specific amino acid formulation if severe impairment (GFR <25 mL/min).
Liver impairment	Child-Pugh B or C: Contraindicated; avoid in hepatic encephalopathy. In mild impairment (Child-Pugh A), use with caution and monitor ammonia.
Pediatric use	Weight-based: 1.5-3 g/kg/day of amino acids (equivalent to 54-109 mL/kg/day of this solution) with dextrose 3-6 mg/kg/min. Titrate based on metabolic tolerance.
Geriatric use	Elderly: Initiate at lower doses (e.g., 50-75% of standard) due to decreased renal function; monitor fluid and electrolyte balance closely; use with caution in heart failure.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER (TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER).

Breastfeeding	Travasol 2.75% in Dextrose 15% is a standard component of parenteral nutrition; components are normally present in human milk. No specific M/P ratio available. Use during lactation is considered safe when medically indicated.
Teratogenic Risk	Parenteral amino acid and dextrose solutions are essential nutrients; no teratogenic risk documented in first trimester. Use in second and third trimesters is common for maternal nutritional support without known fetal harm. However, hyperglycemia or electrolyte imbalances from improper administration may indirectly affect fetal development.